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Abstract Antisense oligonucleotides and small interfering
RNAs, which suppress the translation of specific mRNA
target proteins, are emerging as important therapeutic mo-
dalities for the treatment of cardiovascular disease. Over the
last 25 years, the advances in all aspects of antisense tech-
nology, as well as a detailed understanding of the mechanism
of action of antisense drugs, have enabled their use as ther-
apeutic agents. These advancements culminated in the FDA
approval of the first chronically administered cardiovascular
antisense therapeutic, mipomersen, which targets hepatic
apolipoprotein B mRNA. This review provides a brief his-
tory of antisense technology, highlights the progression of
mipomersen from preclinical studies to multiple Phase III
registration trials, and gives an update on the status of other
cardiovascular antisense therapeutics currently in the clinic.
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Introduction
Antisense oligonucleotides (ASOs) are highly selective ther-
apeutics that have demonstrated broad in vitro and in vivo
activities and produced clinical benefit based upon a concept
originally proposed in 1978 [1]. These drugs are short (12–
20-mer) nucleic acid sequences that bind, via Watson–Crick
hybridization, to their complementary RNA substrates, which
are their receptors. Upon hybridization, ASOs inactivate RNA
via two predominant termination mechanisms: (1) occupancy
only, in which the binding of the ASO leads to translational
arrest, inhibition of splicing, or induction of alternatively
spliced variants, or (2) occupancy-induced destabilization, in
which the RNA/DNA duplex is recognized and degraded by
ribonuclease H1 (RNase H1), a ubiquitously expressed cellu-
lar endonuclease [2]. ASOs employing the RNase H pathway
are widely used in the clinical setting, and this destabilization
mechanism is utilized by all of the ASOs featured in this
review.
The evolution of antisense technology from a simple cell-
free experiment to a bona fide therapeutic platform was not
trivial. For example, unmodified phosphodiester DNAASOs
had little therapeutic benefit due to their short half-lives, poor
tissue distribution, and low affinity for RNA targets. There-
fore, one of the initial steps that led to significant improve-
ments in the pharmacology of ASOs was the replacement of
the native phosphates in the backbone, which are highly
sensitive to plasma and tissue exo- and endonucleases, with
phosphorothioates (PSs) [3]. While the PS modification sig-
nificantly improved stability and tissue distribution by enhanc-
ing plasma protein binding and prolonging tissue half-lives
(1–3 days), the addition of the sulfur also tended to increase
ASO pro-inflammatory properties. Second-generation ASOs
involved altering the sugar moiety (see Fig. 1), with the most
well characterized incorporating a methoxyethyl to the 2′ po-
sition (2′-MOE) or, alternatively, by tethering of the 4′-carbon
to the 2′-hydroxyl of the ribose ring to create the bicyclic
locked nucleic acid (LNA). These changes increased the melt-
ing temperatures of the RNA/ASO duplexes by 2–5 °C/mod-
ification and resulted in an increased affinity for the RNA
substrate [2, 4, 5]. In addition, the proximity of the 2′ modifi-
cation to the 3′-phosphate likely created a steric hindrance that
improved nuclease resistance [6] and altered non-specific pro-
tein binding, thus markedly reducing the pro-inflammatory
properties of the ASOs [7]. Unfortunately, when added uni-
formly, both sugar modifications also made the ASO/RNA
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target duplex a poor substrate for the RNase H enzyme. To
circumvent this, a “gapmer” design was implemented (see
Fig. 1), in which the flanking regions of the ASO contain
the 2′-MOE or LNA modifications while the center of the
compound maintains unmodified sugars that serve as suitable
substrates for RNase H-mediated cleavage [8].
With the enhanced stability, increase in potency, and re-
ductions in non-specific toxicities, second-generation ASOs
(2′-MOE gapmers) have been widely used in vivo. Since
these drugs are readily soluble in saline, they can be admin-
istered without special formulation by multiple routes (sub-
cutaneous, intravenous, intravitreal, topical, aerosol, oral, or
enema) [9]. Tissue distribution of parenterally administered
ASOs, which has been characterized extensively in preclinical
models, is predominantly within the liver, kidney, and spleen
with lesser distribution observed in the heart, ovaries, pancre-
as, testes, and uterus [10, 11]. ASOs accumulate in cells
through either a non-productive pathway, resulting in accu-
mulation of drug into lysosomes, or a productive, endocytotic
process whereby the drug gains access to the target mRNA
[9]. Tissue half-lives of 2′-MOE gapmers range from 10 to 30
days, and typically, reductions inmRNA and protein in animal
models can be observed as early as 24–48 h after initial
dosing, with maximal efficacy occurring after 1 month of
repeated administration [12]. In general, second-generation
drugs have an attractive safety profile, both preclinically and
in the clinic. The most commonly reported adverse events are
transient injection site reactions, which are characterized by
mild to moderate erythema, and flu-like symptoms [13].
Small interfering RNA (siRNA) represents another anti-
sense mechanism used to reduce target mRNA expression
[14]. SiRNAs are delivered as a duplex to the RNA-induced
silencing complex (RISC), which contains several proteins
including Argonaute 2 (Ago2), another cellular endonuclease.
Ago2 cleaves the siRNA duplex into a guide and a passenger
strand, while the RISC complex retains the guide strand and
releases the passenger strand [15]. The RISC/guide strand
forms a haloenzyme which can then bind its single-strand
mRNA complement and cleave via an Ago2-mediated pro-
cess [16]. Due to their inherent chemical properties, siRNAs
must be formulated with lipid conjugates or nanoparticles for
effective in vivo drug delivery [17].
Finally, another antisense approach uses the microRNA
(miRNA) pathway. MiRNAs are endogenous non-coding
RNAs, approximately 22 nucleotides in length, that post-
transcriptionally regulate numerous cellular and metabolic
pathways [18]. Two strategies have evolved to alter miRNA
activity, the first using synthetic mimicry of naturally occur-
ring miRNAs, while the second blocks activity via comple-
mentary ASO inhibitors [19]. However, this relatively new
antisense approach is still in preclinical development and
will not be discussed in this review.
ASOs have been successfully used for a variety of disease
states, including cancer [20–22], viral infection [23], insulin
a
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Fig. 1 Overview of ASO
modifications. a Chemical
structure of the 2′4′-locked nucleic
acid (LNA) and the 2′-O-
methoxyethyl RNA (MOE). b
Schematic of the gapmer ASO
design. In order to facilitate RNase
H activity, unmodified DNA is
included in the internal, typically
ten, nucleotides (“the gap”). The
gap is flanked on the 5′ and 3′ ends
with two to five of the MOE/
LNA-modified nucleotides, which
enhances ASO stability and
affinity for the target RNA
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resistance [24, 25], neurological/neuromuscular diseases
[26, 27], inflammatory diseases [7], and ocular diseases
[28, 29]. However, this review will primarily focus on the
clinical successes of ASOs in cardiovascular disease.
Kynamro
The most advanced antisense drug is mipomersen sodium
(trade name Kynamro, Table 1), a second-generation 2′-MOE
gapmer ASO that targets the messenger RNA (mRNA) of
apolipoprotein B (apoB) [30]. ApoB is the main structural
component of the atherogenic lipoproteins VLDL, IDL, and
LDL, collectively referred to as non-high-density lipoprotein
(non-HDL). It is well established that plasma apoB, LDL
cholesterol (LDL-C), and non-HDL cholesterol (non-HDL-C)
are positively associated with coronary heart disease [31].
While the HMG-CoA reductase small molecule inhibitors
(statins) have proven to be invaluable drugs for lowering
LDL-C in the general population, there are still a significant
number of patients at high risk for a cardiovascular event due,
in part to, the inability to achieve their target LDL-C concen-
trations [32]. Familial hypercholesterolemic (FH) patients are
at greatest risk, due to mutations in their LDL receptor which
render them unable to clear plasma apoB-containing lipopro-
teins, resulting in markedly elevated plasma non-HDL-C con-
centrations and early onset of coronary heart disease (CHD)
[33]. Because raising LDL receptor levels is the primary mech-
anism by which statins reduce circulating LDL-C, the efficacy
of these drugs in the FH patient population has been limited
[34]. Therefore, apoB represents an attractive molecular target
for the antisense technology as (1) it is primarily expressed in
the liver and (2) it does not possess enzymatic activity, making
it “undruggable” by traditional small molecule inhibitors. In
addition, since mipomersen inhibits apoB lipoprotein particle
production and not LDL receptor clearance, it was initially
hypothesized that administration of the drug would be useful
in treating the high-risk FH patient population. Based upon
these attributes, as well as positive clinical efficacy data, ac-
ceptable safety, and tolerability in preclinical models and in
patients, the development of mipomersen by Isis Pharmaceuti-
cals and Genzyme, a Sanofi Company, ultimately led to FDA
approval for its use as an adjunct to lipid-lowering medications
and diet to reduce LDL-C, apoB, total cholesterol, and non-
HDL-C in patients with homozygous FH [35].
In preclinical studies, mice administered a murine apoB
ASO produced dose-dependent reductions in hepatic apoB
mRNA and protein, and concurrent reductions in plasma apoB,
cholesterol, and LDL-C [36]. Subsequent studies in low-
density lipoprotein receptor (LDLR) −/− mice demonstrated
expected suppression of atherogenic lipoproteins with concom-
itant dose-dependent reductions in aortic atherosclerosis [37].
Interestingly, despite reducing VLDL secretion, an event that
could potentially lead to hepatic triglyceride (TG) accumula-
tion, chronic administration of the murine apoB ASO did not
produce such changes [36–38]. While the precise underlying
mechanisms are still under investigation, it was shown in part to
be due to the up-regulation of fatty acid oxidation and down-
regulation of lipogenic genes such as sterol response element
binding protein 1-c (SREBP1-c), acetyl-CoA carboxylase 1,
and hepatic fatty acid synthase (FASN) with a tendency to
suppress hepatic fatty acid synthesis. This observation was also
made in mice harboring the apoB 38.9 truncation [39]. Further
preclinical studies demonstrated that, much like mice, admin-
istration of the apoB ASO to rats, hamsters, rabbits, and mon-
keys led to reductions in hepatic apoB mRNA and protein, and
concomitant reduction in plasma apoB, cholesterol, and LDL-C
[30]. In addition, transcriptional profiling of livers from mon-
keys administered a monkey apoB ASO demonstrated similar
reductions in lipogenic genes such as SREBP1-c and FASN.
Table 1 Summary of antisense drugs approved or in clinical trials
Drug name Drug target Cardiovascular effect Current status
Kynamro Apolipoprotein B Lowers plasma apoB, TPC, LDL-C,
non-HDL-C, and Lp(a)
FDA approval for its use as an adjunct to lipid-lowering
medications for homozygous FH patients
SPC4955 Apolipoprotein B Lowers plasma apoB, TPC, LDL-C,
non-HDL-C, and Lp(a)
Phase I (completed)
ApoC-IIIRx Apolipoprotein C-III Lowers plasma apoC-III and TG Phase I (completed), Phase II initiated
FXIRx Factor XI Prevents thrombosis Phase I (completed)
BMS-844421 PCSK9 Lowers plasma apoB, TPC, LDL-C,
and non-HDL-C
Phase I (terminated)
SPC5001 PCSK9 Lowers plasma apoB, TPC, LDL-C,
and non-HDL-C
Phase I (terminated)
ALN-PCS02 PCSK9 Lowers plasma apoB, TPC, LDL-C,
and non-HDL-C
Phase I (completed)
ApoARx Apolipoprotein(a) Lowers Lp(a) Phase I initiated
TPC total plasma cholesterol
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Consistent with these compensatory effects, the monkeys, like
the mice, did not develop hepatic steatosis.
In the first short-term placebo-controlled, double-blind, dose-
escalation Phase I trial [40], subcutaneous (SC) administration
of mipomersen to healthy volunteers was efficacious. Dose-
dependent reductions occurred in both apoB and LDL-C levels
relative to baseline, with the 200-mg dose of mipomersen pro-
ducing a maximum apoB reduction of 50 % and a maximum
LDL-C reduction of 35 %. The observed pharmacology corre-
lated with drug exposure as estimated by the area under the
curve for drug plasma trough levels. In subjects who received
the 200-mg dose, the drug’s terminal elimination half-life was
approximately 30 days. This durability was reflected by
prolonged pharmacology, where apoB and LDL-C levels
remained below baseline for 3 months after treatment in most
subjects (six of eight) of the 200 mg dose group. No significant
changes occurred in HDL-C levels across all dose groups.
In a second Phase I trial designed to evaluate clinical
pharmacokinetics, mipomersen was coadministered with ei-
ther simvastatin, an HMG-CoA reductase inhibitor, or
ezetimibe, a drug that blocks cholesterol absorption [41].
The results from this study demonstrated no clinically relevant
pharmacokinetic interactions between mipomersen and the
other dyslipidemia agents. Further to these results, in vitro
assays demonstrated no effect of mipomersen on cytochrome
P450 activity or P-glycoprotein.
Several short-term randomized, placebo-controlled, dose-
escalation Phase II trials were performed where mipomersen
was evaluated as a single agent [42] and as an add-on to stable
lipid-lowering therapy [43, 44] in subjects with varying de-
grees of hyperlipidemia. As a monotherapy, mipomersen pro-
duced reductions from baseline of −7 to −71% in LDL-C after
13 weeks of dosing at 50 to 400 mg/week, respectively. A
large proportion of subjects who received ≥200 mg/week
mipomersen (19 of 24) achieved LDL-C levels below 2.6
mmol/L (100 mg/dL), where the mean baseline level of
mipomersen-treated subjects was 4.5 mmol/L (170 mg/dL).
Parallel dose-dependent reductions occurred in apoB and non-
HDL-C. Indeed, half of the subjects who received the highest
dose of 400 mg/week mipomersen achieved apoB levels at or
below the limit of detection of 35 g/L by week 12.
A similar profile was observed when mipomersen treat-
ment was added to ongoing stable statin therapy [43]. In a 5-
week dose-escalation Phase II study, subjects who received
the 200-mg dose of mipomersen had a significant mean
reduction in LDL-C of −27 % from baseline while the 400-
mg dose resulted to a mean reduction of −38 %. Parallel
reductions occurred in apoB and non-HDL-C. In a separate
cohort, administration of mipomersen (200 mg) weekly led
to 36 % reduction in both apoB and LDL-C from baseline
after 13 weeks of treatment.
A third dose-escalation Phase II trial involved subjects
diagnosed with heterozygous FH on stable lipid-lowering
therapy who received 50 to 300 mg/week mipomersen, or
placebo, over a 6-week treatment period [44]. In this study
population, LDL-C was significantly reduced from baseline
compared to pooled placebo in the 200 and 300 mg/week
dose groups by −21 and −34 %, respectively, with concor-
dant dose-dependent reductions in apoB, non-HDL-C, and
total cholesterol. Subjects assigned to the 300 mg/week
cohort continued once-weekly dosing for an additional 7
weeks to achieve a mean reduction of −37 % in LDL-C
and apoB from baseline, 1 week after the last dose.
Overall, mipomersen was well tolerated in each of the
three short-term Phase II trials. The most common adverse
event reported was injection site reactions (ISRs), a common
side effect of subcutaneously administered drugs [45–47].
Elevations in liver transaminases, which were reversible
upon continued dosing or once the drug was discontinued,
occurred in a limited number of subjects treated with
mipomersen at doses of 200 mg or higher. These elevations
were asymptomatic and not accompanied by abnormalities
in other measures of liver function, such as total bilirubin,
albumin, and prothrombin. There were no clinically relevant
changes or treatment effects in other safety and laboratory
assessments, such as vital signs, electrocardiograms, renal
function tests, coagulation, and urinalyses.
Three 26-week randomized, placebo-controlled Phase III
trials that enrolled FH patients with a range of risk and
severity of cardiovascular disease were also conducted
[48–50]. The first trial evaluated the effects of mipomersen
in patients with the most severe form of this genetic disease,
homozygous FH [48]. Homozygous FH patients on stable
low-fat diets and maximally tolerated lipid-lowering therapy
(LLT) were administered once-weekly SC doses of either
mipomersen (200 mg) (n=34) or placebo (n=17) for 26
weeks. Dose adjustments were not permitted. The mean
age was 31 years, and 44 of 51 patients (86 %) were taking
the maximum dose of a statin or other LLT. Two weeks
following the final dose, patients who received mipomersen
showed a significant mean reduction in plasma LDL-C (−25
vs. −3 % placebo, p=0.0003) from a mean baseline level of
11.4 mmol/L (440 mg/dL). This response corresponded to a
mean absolute reduction of −2.9 mmol/L (−113 mg/dL) in
LDL-C. Furthermore, plasma apoB levels decreased by a
significant amount relative to baseline (−27 vs. −3 % place-
bo, p<0.0001). Notably, a significant increase in HDL-C
levels from baseline occurred in mipomersen-treated patients
(+15 vs. +4 % placebo, p=0.03).
The second Phase III trial involved heterozygous FH
patients with stable coronary artery disease [49]. Patients
were administered either mipomersen (200 mg) (n=83) or
placebo (n=41) once weekly (SC administration) for 26
weeks as an add-on to ongoing maximum tolerated dose of
a statin and stable LLT. The mean age was 56 years, and 81
of 124 patients (65 %) were taking the maximum dose of a
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statin. Two weeks following the final dose, patients who
received mipomersen experienced a significant reduction in
plasma LDL-C (−28 vs. +5.2 % placebo, p<0.001) from a
mean baseline level of 4.0 mmol/L (153 mg/dL). This re-
sponse corresponded to a mean absolute reduction of −1.3
mmol/L (−49 mg/dL) in LDL-C. ApoB also decreased by a
significant amount relative to baseline (−26 vs. +7 % place-
bo, p<0.001), as did other apoB-containing lipoproteins
such as non-HDL-C and lipoprotein (a) (Lp(a)). Assessment
of liver TG content by magnetic resonance imaging at base-
line and end of treatment showed a median increase in liver
fat content of +4.9 % in mipomersen-treated patients, com-
pared to +0.4 % in placebo.
The third Phase III trial evaluated mipomersen in patients
with severe hypercholesterolemia (HC). Severe HC was
defined as LDL-C greater than or equal to 7.8 mmol/L (300
mg/dL), or LDL-C≥5.1 mmol/L (200 mg/dL) with pre-
existing CHD, while on a maximum tolerated statin dose
and stable LLT [50]. Patients were administered once-
weekly SC doses of either mipomersen (200 mg) (n=39) or
placebo (n=19) for 26 weeks as an add-on to ongoing
therapy. The mean age was 51 years, and 24 of 58 patients
(41 %) were taking a maximum statin dose. Two weeks
following the final dose, patients who received mipomersen
experienced a significant reduction in plasma LDL-C (−36
vs. +13 % placebo, p<0.001) from a mean baseline level of
7.2 mmol/L (276 mg/dL). This response corresponded to a
mean absolute reduction of −2.6 mmol/L (−101 mg/dL) in
LDL-C. ApoB decreased to a similar extent relative to base-
line (−36 vs. +11 % placebo, p<0.001).
Mipomersen has also been evaluated for safety and efficacy
in two other high-risk CHD populations based on the same
study design as the aforementioned Phase III trials [51, 52].
One was a Phase III trial that involved patients at high risk for
CHD and with LDL-C levels greater than or equal to 2.6
mmol/L (100 mg/dL) despite treatment with a maximum toler-
ated statin dose and LLT [52]. In this study, 88 of 153 random-
ized patients (56 %) were type 2 diabetics. The other 26-week
placebo-controlled trial involved subjects with uncontrolled
LDL-C levels (≥3.4 mmol/L) who were intolerant to statins
[51]. Nearly half of the subjects (15 of 33) in this studywere not
taking lipid-lowering medications. Mipomersen produced ro-
bust reductions in LDL-C from baseline compared to placebo
in both study populations, with a mean percentage change from
baseline of −37 % (vs. −5 % placebo, p<0.001) and −47 %
(vs. −2 % placebo, p<0.001) 2 weeks after the last dose,
respectively. Concordant reductions occurred in all apoB-
containing lipoproteins tested, including non-HDL-C and Lp(a).
No new safety concerns emerged in the Phase III trials.
Consistent with previous studies, the most common side
effects experienced by patients were ISRs and flu-like symp-
toms. A limited number of patients also experienced persis-
tent elevations in liver transaminase levels. These increases
were not accompanied by abnormalities in other measures of
liver function, were largely reversible with continued treat-
ment or otherwise, and receded back to baseline values in
post-dose follow-up. Beyond these findings, no additional
safety issues have been identified in the corresponding Phase
III open-label extension trial [53]. Notably, increases in liver
fat content have tended to stabilize or decrease after 1 year of
treatment in patients participating in the Phase III extension.
This trend may reflect compensatory changes in hepatic lipid
metabolism first observed in the preclinical animal model
studies.
As described above, mipomersen has been approved by
the FDA for use as an adjunct to first-line therapies in
homozygous FH patients to reduce LDL-C, non-HDL-C,
apoB, and total cholesterol. Another randomized, double-
blind, placebo-controlled Phase III trial is currently in prog-
ress to assess the safety and efficacy of an alternative lower
and more frequent dose regimen and the approved 200-mg
weekly dose regimen in patients with severe FH [6]. The
estimated study completion date is late 2014. Positive safety
and efficacy data will further support consideration of
mipomersen for use as an adjunct to existing therapies in
other high-risk patient populations.
In addition to mipomersen, both siRNA and LNA oligo-
nucleotides targeting apoB mRNA have been studied [54,
55]. Currently, the siRNA has only been evaluated in rodents
and non-human primates, but at the time of this publication
had not advanced into clinical trials. A multiple-ascending-
dose Phase I clinical trial in 18 healthy subjects with the
apoB LNA (SPC4955) was completed in November 2011,
but at present, the outcome of the trial has not been disclosed
[56], nor have any other clinical trials been initiated.
ISIS-APOCIIIRx
Hypertriglyceridemia (HTG) is an independent risk factor
for cardiovascular disease [57] and pancreatitis [58, 59].
Furthermore, it has been shown that reducing plasma TG
below 5.7 mmol/L (500 mg/dL) in severe HTG patients had
both clinical and economic benefits [60].
Apolipoprotein C-III (apoC-III) is an important regulatory
factor in plasma TG homeostasis. It is a 79-amino acid
glycoprotein that is present on all lipoprotein classes, with
the majority found on HDL particles (60 % of total plasma
apoC-III) and less on the apoB-containing lipoprotein parti-
cles (20, 10, and 10 % of total plasma [61] apoC-III is found
on VLDL, IDL, and LDL, respectively) [62]. Studies in
animal models and humans indicate that apoC-III affects
plasma TG catabolism. In mice, over-expression of apoC-
III leads to marked HTG [63, 64], while genetic knockout
results in reductions in plasma TG [65, 66]. The importance
of apoC-III was highlighted in an Old World Amish
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population where a heterozygous loss-of-function allele for
APOC3 resulted in significantly reduced plasma TG and
LDL-C, as well as increased HDL-C [67]. In contrast, it
was found that gain-of-function mutations in the APOC3
promoter in an Asian Indian population led to significantly
increased fasting plasma TG levels [68]. While the exact
mechanism by which apoC-III exerts its effects is unclear,
there is evidence that it may act directly by inhibiting lipo-
protein lipase [69], reducing clearance of TG-rich lipopro-
teins [70], and enhancing hepatic TG secretion [71]. How-
ever, the relative contribution of each of these pathways is
uncertain.
Analysis of the Cholesterol and Recurrent Events trial
showed that in a model which adjusted for LDL-C, VLDL-
C, TG, and HDL-C, apoC-III VLDL+LDL remained an inde-
pendent risk factor for a recurrent event [72], indicating that the
pro-atherogenic properties of apoC-III extend beyond its role
in TG metabolism. Subsequent studies have shown that apoC-
III found on apoB-containing particles has pro-inflammatory
properties via enhancing adhesion of monocytic cells to endo-
thelial cells [73] and downstream induction of endothelial cell
vascular cell adhesion molecule I [74].
In addition to its pro-atherogenic effects, elevated plasma
apoC-III concentrations have also been implicated in the
development of insulin resistance and diabetes in both pre-
clinical and human epidemiology studies. ApoC-III protein
expression has been shown to be regulated by insulin [75]
via a Foxo1-mediated process [76]. Indeed, dietary-
challenged transgenic mice over-expressing human APOC3
had significantly elevated insulin levels with no difference in
glucose, indicating insulin resistance [64]. In humans, vari-
ants in an insulin response element of the APOC3 promoter
led to loss of insulin-mediated apoC-III transcriptional reg-
ulation. This was later associated with an increased incidence
of NAFLD and insulin resistance in an Asian Indian popu-
lation [68]. However, this result was not replicated in a
second study performed in an African–American population
[77]. It is also interesting to note that a group of Ashkenazi
Jews harboring a loss-of-function mutation in APOC3 that
only lowered plasma apoC-III protein by 30 % did not
significantly change plasma TG, but remained associated
with improved insulin sensitivity, lower blood pressure,
and increased longevity [78], further suggesting the involve-
ment of apoC-III in multiple, complex metabolic pathways.
Due to the large body of evidence summarized above
implicating apoC-III in cardiovascular and metabolic disease
progression, apoC-III ASOs were developed targeting mouse,
rat, monkey, and human transcripts [79]. In several mouse and
rodent models, administration of apoC-III ASO led to signif-
icant dose-dependent reductions in apoC-III and concomitant
significant reductions in plasma TG. Administration of apoC-
III ASO to apoC3 −/− mice had no effect on plasma TG,
indicating that the TG-lowering effects of the apoC-III ASO
were target specific. Hepatic TG secretion in apoC-III ASO-
treated C57BL/6mice receiving poloxamer 407, which blocks
apoB particle clearance allowing for quantitation of apoB
secretion [80], was not different compared to that in controls,
suggesting that the TG-lowering effects of the apoC-III ASO
were due to changes in clearance, not hepatic secretion. Ad-
ministration of apoC-III ASO to HTG rhesus monkeys also
led to significant dose-dependent reductions in plasma apoC-
III mRNAwith subsequent reduction in plasma TG.
Due to significant and consistent TG-lowering effects in
multiple preclinical species with no apparent tolerability issues,
a Phase I clinical trial of the human apoC-III ASO (ISIS-
APOCIIIRx-ISIS 308401), a 5–10–5 MOE gapmer, was initiat-
ed. This double-blind, placebo-controlled, dose-escalation stud-
y, in which patients were dosed for 4 weeks with 50, 100, 200,
or 400 mg of ISIS-APOCIIIRx, was performed in healthy
human volunteers to assess safety, pharmacokinetics, and phar-
macodynamics [79]. As observed in preclinical studies, admin-
istration of ISIS 308401 led to significant dose-dependent re-
ductions in apoC-III protein with concomitant reductions in
plasma TG (−50 %) relative to baseline at the highest admin-
istered dose. Reductions in plasma apoC-III protein and TG
were seen as early as 8 days after the initial dose [79]. ISIS
308401 was generally well tolerated with no serious adverse
events or early dosing terminations. Consistent with adminis-
tration of other second-generation antisense drugs, the most
common adverse events were ISRs. The successful completion
of this Phase I trial in healthy human volunteers has since led to
Phase II trials in subjects with very high TG levels [61] and
those with moderately high TG levels and type 2 diabetes [81].
ISIS-FXIRx
Precise control of the coagulation cascade at sites of vessel
wall injury leads to thrombin production and the formation
of a hemostatic plug. Patients with low levels of coagulation
factor XI (FXI) have a reduced risk for thromboembolic
diseases [37, 38] with no associated bleeding issues, dem-
onstrating that FXI appears to play only a minor role in
hemostasis [82, 83]. Increased FXI levels in patients may
result in increased risk of venous thrombosis, myocardial
infarction, and stroke [84, 85]. Further, several preclinical
studies demonstrating the importance of FXI in thrombosis
[86–91], with minimal contribution to hemostasis, validate
FXI as an attractive pharmacological target.
To further characterize the role of coagulation factors in
thrombosis, mouse-specific ASOs were developed to specif-
ically deplete the expression of individual coagulation fac-
tors. Mouse studies utilizing FXI-specific ASOs demonstrat-
ed that inhibition of FXI mRNA in the liver led to reduced
levels of plasma FXI protein and activity [92]. The measured
anticoagulant effect after ASO depletion of FXI resulted in a
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dose-dependent prolongation of activated partial thrombo-
plastin time (aPTT) with no effect on prothrombin time. The
treatment of mice with FXI ASOs resulted in antithrombotic
effects in the FeCl3-induced IVC thrombosis model with no
increased bleeding. The use of warfarin in that study was
effective at reducing thrombosis, but increased bleeding. FXI
ASO treatment was also effective at reducing thrombosis in a
mesenteric vein and stenosis-induced mouse model without
increased bleeding [92]. To determine the safety and effec-
tiveness of FXI ASOs in combination with standard of care
agents, studies were carried out with either an anticoagulant
(Lovenox®) or an antiplatelet drug (Plavix®). Results from
these experiments demonstrated increased antithrombotic
activity without enhancement in bleeding risk [92].
To evaluate the safety and pharmacodynamic profile of
FXI ASOs in primates, the drug was subcutaneously admin-
istered for 13 weeks in cynomolgus monkeys [93]. Those
results demonstrated a dose-dependent reduction of FXI
mRNA level in the liver and plasma with a corresponding
increase in aPTT. The potential for increased bleeding after
FXI inhibition was examined in tissues of high fibrinolytic
activity using surgical models (oral mucosa and partial tail
amputation) in addition to tissues with low intrinsic fibrino-
lytic activity (skin laceration). A 70 % reduction in plasma
FXI activity after FXI ASO treatment resulted in no enhance-
ment in bleeding time or blood volume loss, while enoxaparin
treatment increased both endpoint measurements [93].
Patients with severe FXI deficiency have reduced risk for
thrombosis, and baboons treated with a monoclonal antibody
(Mab) against FXI, which reduces FXI levels in plasma by
99 %, have reduced thrombosis in a well-characterized baboon
model of thrombosis and hemostasis [88]. Importantly, no
increased bleeding was observed with almost complete inhibi-
tion of FXI in these monkeys. To define anticoagulation and
antithrombotic activity that might ultimately be achieved in
clinical applications in humans, the minimal level of FXI
reduction in primates required to achieve antithrombotic activ-
ity was assessed in a baboon model of thrombosis and hemo-
stasis [94]. First, the FXI Mab was titrated in these animals to
estimate the level of FXI required for antithrombotic activity
followed by administration of FXI ASOs until the estimated
antithrombotic levels were achieved. An intravenous injection
of FXI Mab inhibited both FXI plasma activity and platelet
deposition in a propagating thrombus by 50 % [94]. The FXI
ASO was then administered by subcutaneous injection three
times per week at a dose of 25 mg/kg, reducing FXI protein
and activity levels by 50 % while increasing aPTT. Further,
when FXI plasma levels were reduced to less than 50 % of the
normal, thrombin generation was almost completely abolished
[94]. Finally, ASO reduction of FXI plasma levels did not
increase bleeding in baboons.
The safety, tolerability, and pharmacodynamics of ISIS-
FXIRx were evaluated in a double-blind, ascending-dose,
placebo-controlled Phase I study in healthy subjects after a
6-week treatment period. Treatment with ISIS-FXIRx demon-
strated a robust, sustained, and dose-dependent reduction in
FXI protein and activity that was accompanied by a concom-
itant increase in aPTT [95]. No study drug-related bleeding
events were reported even in subjects in whom plasma FXI
activity levels were reduced to undetectable levels. ISIS-
FXIRx did not cause clinically significant changes in vital
signs, ECG, hepatic function, renal function, or hematology.
These data are consistent with preclinical data obtained in
multiple species and provide support for development of
ISIS-FXIRx as a novel approach for the treatment and preven-
tion of thromboembolic disorders.
PCSK9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a
member of the proprotein convertase family of proteases.
Epidemiological studies have suggested that loss-of-function
mutations in PCSK9 result in lifelong reductions in LDL-C
that are associated with significant reductions in the inci-
dence of coronary heart disease [96–99]. Pcsk9-deficient
mice exhibited twofold increases in hepatic LDLRs and
significant reductions in LDL via enhanced hepatic clearance
[96]. The binding site of PCSK9 to the LDLRs was identified
as the first epidermal growth factor-like repeat (EGF-A) in
the EGF homology domain [97]. PCSK9 binding to EGF-A
appears to interfere with a conformational change required
for receptor turnover, effectively shunting LDLRs from
recycling to degradation fates.
Intraperitoneal administration of a murine-specific PCSK9
2′-MOE-modified ASO (ISIS 394814) to high fat-fedmice for
6 weeks reduced total cholesterol and LDL-C by −53 and −
38 %, respectively, and produced a twofold increase in liver
LDLR protein concentrations [100]. Further, ISIS 394814
produced hepatic PCSK9mRNA reductions of 92% vs. saline
after 6 weeks of treatment. To demonstrate that the LDL
lowering produced by the PCSK9 ASO required functional
LDL receptors, studies were also performed in Ldlr-deficient
mice treated with ASO for 6 weeks at 50 mg/kg/week. As
anticipated, in mice genetically lacking LDLR, no reduction
in plasma lipid levels was observed. Based upon these positive
effects in multiple mouse models, high-density screens were
performed in human hepatoma cell lines to identify an optimal
human PCSK9 ASO inhibitor. A subsequent Phase I clinical
trial was conducted evaluating a 2′-MOE-modified human
PCSK9 ASO (BMS-844421) but was terminated by Bristol-
Myers Squibb in January 2011 [101].
A similar lipid-lowering profile was also observed testing
a LNA-modified ASO after IVadministration in mice [102].
Based upon those compelling preclinical findings with the
(LNA) ASO, Santaris Pharma A/S initiated a Phase I clinical
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trial in May 2011 evaluating SPC5001, an optimized human
PCSK9 compound [103]. This trial was also terminated in
November 2011. A recent publication revealed that SPC5001
produced acute renal injury in a single subject following three
weekly doses of 5 mg/kg on days 1, 8, and 15 [104].
Researchers at Alnylam developed active, cross-species
siRNAs capable of targeting PCSK9 expression in rodents,
non-human primates, and humans. For in vivo studies, PCSK9
and control siRNAs were formulated in lipidoid nanoparticles.
Liver-specific siRNA silencing of PCSK9 in mice and rats
reduced PCSK9 mRNA levels by 50–70 % [105] with a
concomitant 60 % reduction in plasma total cholesterol con-
centrations. In PCSK9 transgenic mice, siRNAs suppressed
the human PCSK9 transcript by >70 % while significantly
reduced PCSK9 plasma protein levels. In a non-human primate
study, a single dose of the PCSK9 siRNA targeting resulted in
a rapid lowering of plasma PCSK9, apoB, and LDL, without
affecting HDL or TG levels.
Alnylam initiated a randomized, single-blind, placebo-
controlled, single-ascending-dose Phase I study in healthy
volunteers with elevated LDL-C>3 mmol/L (116 mg/dL) in
September 2011 [106]. As a monotherapy, ALN-PCS02
resulted in statistically meaningful and durable reductions
of plasma PCSK9 of up to 84 % and lowering of LDL-C of
up to 50 %. Results following a single dose of ALN-PCS
support a once-monthly dosing regimen. ALN-PCS02 was
shown to be safe and well tolerated in this study, and there
were no serious adverse events. An additional Phase I trial is
underway to further evaluate ALN-PCS02, an intravenously
administered siRNA, vs. ALN-PCSsc, a subcutaneously ad-
ministered alternate formulation.
Currently the most advanced PCSK9 clinical inhibitors are
humanized Mab. Both Regeneron (REGN727) and Amgen
(AMG145) are conducting multiple Phase II/III trials where
primary outcomes will be determined in tens of thousands of
dyslipidemic subjects [9, 94]. Results obtained from these
ongoing clinical trials will ultimately determine the validity
and safety of targeting PCSK9 as a lipid-lowering therapeutic
approach.
ISIS-APOARx
Lp(a) is a complex lipoprotein particle found in human plasma.
Lp(a) consists of a LDL-like particle with apolipoprotein(a)
(apo(a)) bound to the apoB protein via a disulfide bond. The
apo(a) protein shows a high degree of homology to plasmino-
gen at both the nucleotide and the amino acid level [107].
However, in humans, the apo(a) gene transcript is much larger
due to a repetitive kringle IV domain in the LPA gene. The
majority of apo(a) mRNA is expressed in the liver, with minor
amounts present in the testis, brain, adrenals, lung, and pitui-
tary. Elevated Lp(a) levels are an independent risk factor for
the development of cardiovascular disease, peripheral vascular,
and cerebrovascular disease [108, 109]. Recently a genome-
wide association study identified a SNP in the LPA locus that
was significantly associated with aortic valve calcification
across several ethnic groups [110]. While extensive epidemio-
logical evidence indicates that elevated plasma Lp(a) levels are
pro-atherogenic [111], the molecular mechanisms by which it
contributes to the atherosclerotic process remain enigmatic.
There is evidence that apo(a) may impair fibrinolysis of throm-
bosis, accelerate macrophage foam cell formation [112], and
act as a sink for oxidized phospholipids [113].
Due to the expanding evidence indicating that Lp(a) con-
tributes to CAD, a human apo(a)-specific ASO was developed
and characterized in three human LPA transgenic mouse
models: (1) mice expressing a human LPA construct (8K-LPA
mouse) and (2) mice expressing human APOB and the human
LPA construct (8K-LPA and transgenic mice expressing the
natural human apo(a) gene in a yeast artificial chromosome
(12K-LPA)) [114].Mice treated for 4 weeks showed significant
reductions in hepatic apo(a) mRNA expression, with the ASO
showing greater efficacy in the 12K-LPA (87 % reduction
compared to saline) relative to the 8K-LPA and in the 8K-
LPA (52 % reduction). In the 12K-LPA mouse, apo(a) ASO
treatment significantly reduced plasma apo(a) protein levels
(11,060±7,137 vs. 76,983±14,598 RLU at baseline) and
OxPL/m-apoB (9,965±907 vs. 28,003±2,573 RLU at base-
line). These encouraging preclinical results provided the im-
petus to initiate a Phase I trial in March 2013 to assess the
efficacy and safety of the APOARx in healthy human volun-
teers. Results from these ongoing trials will define the potential
therapeutic benefit of reducing plasma apo(a) levels in
dyslipidemic patients.
Summary
After more than 30 years of basic research and a significant
investment in nucleic acid-based medicinal chemistry opti-
mization, antisense technology has emerged as a third ther-
apeutic platform, distinct from small molecule and protein-
based approaches, for the treatment of a wide variety of
disease indications. Extensive preclinical research and clin-
ical experience with second-generation ASOs have demon-
strated that these drugs are safe and efficacious agents that
can selectively reduce the expression of a wide variety of
disease-associated proteins. Further, the inherent specificity
of the ASO-mediated mRNA termination mechanism allows
for precise isoform targeting, which has proven difficult with
other drug classes. Mipomersen, the first systemic antisense
drug approved by the FDA for the treatment of hypercholes-
terolemia in HoFH patients, represents the first of many other
therapeutic opportunities in clinical development. In addition
to dyslipidemia indications, ASOs targeting inflammation,
976 J. of Cardiovasc. Trans. Res. (2013) 6:969–980
cancer, coagulation, neurological diseases, metabolic syn-
drome, rare genetic disease, and splicing disorders are cur-
rently advancing in the clinic.
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